Minerva Neurosciences Inc (NERV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Minerva Neurosciences Inc (NERV) has a cash flow conversion efficiency ratio of 21.365x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.43 Billion) by net assets ($-254.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Minerva Neurosciences Inc (NERV) balance sheet quality index to measure how much of total assets are equity-financed.
Minerva Neurosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Minerva Neurosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NERV cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Minerva Neurosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Minerva Neurosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Globa Terra Acquisition Corporation Class A Ordinary Shares
NASDAQ:GTERA
|
-0.001x |
|
Hi-Tech Pipes Limited
NSE:HITECH
|
-0.011x |
|
Catella AB (publ)
ST:CAT-B
|
0.009x |
|
Even Construtora e Incorporadora S.A
SA:EVEN3
|
-0.038x |
|
JVM Co. Ltd
KQ:054950
|
0.035x |
|
Fanhua Inc.
NASDAQ:AIFU
|
0.117x |
|
Hong Leong Capital Bhd
KLSE:5274
|
-0.159x |
|
BF Investment Limited
NSE:BFINVEST
|
0.001x |
Annual Cash Flow Conversion Efficiency for Minerva Neurosciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Minerva Neurosciences Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Minerva Neurosciences Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-140.75 Million | $-13.51 Billion | 95.994x | +12515.38% |
| 2024-12-31 | $-25.69 Million | $-19.55 Million | 0.761x | +46.46% |
| 2023-12-31 | $-28.46 Million | $-14.78 Million | 0.520x | -57.79% |
| 2022-12-31 | $-20.02 Million | $-24.65 Million | 1.231x | +139.90% |
| 2021-12-31 | $7.98 Million | $-24.60 Million | -3.085x | -380.29% |
| 2020-12-31 | $52.66 Million | $-33.82 Million | -0.642x | +58.92% |
| 2019-12-31 | $27.78 Million | $-43.43 Million | -1.563x | -236.48% |
| 2018-12-31 | $90.26 Million | $-41.94 Million | -0.465x | -2077.04% |
| 2017-12-31 | $131.60 Million | $3.09 Million | 0.024x | +109.70% |
| 2016-12-31 | $105.98 Million | $-25.69 Million | -0.242x | +44.75% |
| 2015-12-31 | $55.32 Million | $-24.27 Million | -0.439x | +37.17% |
| 2014-12-31 | $51.50 Million | $-35.96 Million | -0.698x | -552.28% |
| 2013-12-31 | $20.18 Million | $-2.16 Million | -0.107x | +99.78% |
| 2012-12-31 | $19.02K | $-908.54K | -47.770x | -- |
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in… Read more